0000000000370729
AUTHOR
D. Travaglini
Advanced earth observation approach for multiscale forest ecosystem services modeling and mapping (MIMOSE)
In the last decade ecosystem services (ES) have been proposed as a method for quantifying the multifunctional role of forest ecosystems. Their spatial distribution on large areas is frequently limited by the lack of information, because field data collection with traditional methods requires much effort in terms of time and cost. In this contribution we propose a methodology (namely, MultIscale Mapping Of ecoSystem servicEs - MIMOSE) based on the integration of remotely sensed images and field observation to produce a wall-to-wall geodatabase of forest parcels accompanied with several information useful as a basis for future trade-off analysis of different ES. Here, we present the applicat…
16. Ottimizzazione del campione dendrometrico
Nell'ambito della redazione del Piano di Gestione della Riserva Naturale Statale biogenetica di Vallombrosa è stata condotta una sperimentazione volta a ottimizzare il tempo di rilievo e la dimensione del campione per il rilievo quantitativo dendrometrico. i risultati evidenziano che la migliore dimensione delle aree di saggio, di forma circolare, verificata sul CV dell'area basimetrica e nell'ottica di minimizzare i tempi di rilievo è pari a 1257 metri quadrati, ovvero un raggio di 20 metri lineari.
Data of safety in a single-center alemtuzumab treated population
Alemtuzumab is approved for highly active MS and, in Europe, can be employed after other disease-modifying treatments (DMTs) as an escalation approach or first therapeutic option. The occurrence of secondary autoimmune adverse events and infections differs depending on the employed approach.In the manuscript entitled “Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: report from a single Italian center” by di Ioia M. and collaborators, efficacy and safety data of alemtuzumab were evaluated in a real-world MS population. The aim of the article is to describe in detail the unexpected serious adverse events which occurred in this cohort during and after the administr…
Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: A report from a single Italian center
Abstract Background Alemtuzumab, is a compound approved for highly active MS, and, in Europe, employed after the use of other disease-modifying treatments (DMTs) with an escalation approach or used as a first therapeutic option. The occurrence of secondary autoimmune adverse events and or infections can differ depending on the employed approach. Objective To evaluate the efficacy and safety of alemtuzumab in real-world MS population that encompassed patients previously treated with other DMTs. Methods 35 patients, treated with alemtuzumab in a single MS Center, were followed for at least 36 months. The study investigated the prevalence of patients reaching the phase of the non-active diseas…